Severe Congenital Protein C Deficiency: Description of a New Mutation and Prophylactic Protein C Therapy and In Vivo Pharmacokinetics

2008 ◽  
Vol 30 (2) ◽  
pp. 166-171 ◽  
Author(s):  
Wendy Y. Tcheng ◽  
Sinisa Dovat ◽  
Zafer Gurel ◽  
Jennifer Donkin ◽  
Wing-Yen Wong
1988 ◽  
Vol 29 (2) ◽  
pp. 120-121 ◽  
Author(s):  
Valerio de Stefano ◽  
Giuseppe Leone ◽  
Luciana Teofili ◽  
Rita Ferrelli ◽  
Giuseppe Pollari ◽  
...  

PEDIATRICS ◽  
1986 ◽  
Vol 77 (5) ◽  
pp. 670-676
Author(s):  
Patrick Yuen ◽  
Alfred Cheung ◽  
Hsiang Ju Lin ◽  
Faith Ho ◽  
Jun Mimuro ◽  
...  

Severe and recurrent purpura fulminans developed in a Chinese boy at one day of age. Results of coagulation studies performed on the patient during attacks were compatible with the diagnosis of disseminated intravascular coagulation. Subsequent investigations have revealed that the patient is homozygous and that his parents are heterozygous for protein C deficiency. Cryoprecipitate and fresh frozen plasma induced a remission, and administration of warfarin has been successful in preventing recurrence of attacks for as long as 8 months without infusion of any plasma components. None of the family members who are heterozygous for protein C deficiency have had thrombotic episodes.


2020 ◽  
Vol 27 (1) ◽  
pp. 100-103
Author(s):  
Kazuki Ueda ◽  
Eriko Morishita ◽  
Hironaga Shiraki ◽  
Shunzo Matsuoka ◽  
Shinsaku Imashuku

2019 ◽  
Vol 41 (4) ◽  
pp. e210-e215 ◽  
Author(s):  
Xiuli Yuan ◽  
Changgang Li ◽  
Xiaowen Chen ◽  
Liwei Liu ◽  
Guosheng Liu ◽  
...  

2020 ◽  
Vol 34 (3) ◽  
pp. 1300-1303
Author(s):  
Darren Kelly ◽  
Florence Juvet ◽  
Gary Moore

Blood ◽  
1993 ◽  
Vol 81 (3) ◽  
pp. 690-695 ◽  
Author(s):  
C Negrier ◽  
M Berruyer ◽  
A Durin ◽  
N Philippe ◽  
M Dechavanne

Abstract We report a quantitative protein C deficiency combined with a factor IX deficiency in a one-year-old boy. The inheritance of the two deficiency states was independent, the factor IX defect coming from the mother and the protein C defect from the father. Both factor IX activity and antigen were below 1%, and protein C activity as well as antigen were close to 27% of normal values. This association raises a real therapeutic and prognostic question. Protein C deficiency is indeed associated with a significant thrombotic risk and some factor IX concentrates seem to carry a potential thrombogenicity, particularly following infusion of repeated doses. We evaluated in this patient the potential activation of the coagulation system by measuring the levels of prothrombin fragment F1 + 2 at the basal state and after a single administration of 20 U/kg of a high purity factor IX concentrate. We found an unexpected basal activation of the hemostatic system before infusion (F1 + 2 = 1.6 nmol/L), which further increased during 8 hours. Despite the clinical predominant expression of the hemophilic trait, our results seem to assess the biologic prevalence of the protein C deficiency. This emphasizes the need for a careful follow-up after infusions of repeated doses of factor IX, as used during a surgical procedure. Furthermore, this raises the question of the prognosis because the risk of thrombotic manifestations associated with a protein C deficiency increases with age. Finally, these results highlight a part of the in vivo activation process of prothrombin in case of failure of the intrinsic pathway of coagulation. The protein C defect seems to be responsible for an upregulation of the prothrombin activation through the extrinsic pathway.


Blood ◽  
1993 ◽  
Vol 82 (1) ◽  
pp. 159-168 ◽  
Author(s):  
S Gandrille ◽  
M Alhenc-Gelas ◽  
P Gaussem ◽  
MF Aillaud ◽  
E Dupuy ◽  
...  

We describe five families presenting with type II hereditary protein C deficiency characterized by normal antigen and amidolytic activity levels but low anticoagulant activity. All the exons and intron/exon junctions of the protein C gene were studied using a strategy combining amplification by the polymerase chain reaction (PCR), denaturing gradient gel electrophoresis of the amplified fragments, and direct sequencing of fragments displaying altered melting behavior. We detected five novel mutations. Three were located in the C-terminal part of the propeptide encoded by exon III: Arginine (Arg)-5 to tryptophan (Trp), Arg-1 to histidine (His), and Arg-1 to cysteine (Cys) mutations. The two others, located in exon IX, affected Arg 229 and serine (Ser) 252, which were respectively replaced by glutamine (Gln) and asparagine (Asn). DNA studies of the other exons from affected individuals showed no other abnormalities. These novel mutations provide further insight into the importance of the affected amino acids located close to the active site, near Asp 257, one of the three amino acids of the catalytic triad. The low anticoagulant activity of the abnormal protein C indicated that Arg 229 and Ser 252 play a key role during the interaction between protein C and its cofactor protein S, phospholipids, or factors Va and VIIIa. The Arg-1 to Cys mutation led to the dimerization of protein C with another plasmatic component, as evidenced by the presence in the plasma of a high molecular weight form of protein C that disappeared after reduction. No molecular mass abnormalities were observed in heavy and light chains of all other protein C mutants. In the five families explored, 9 (64%) of the 14 subjects bearing the mutations reported thrombotic events. This suggests that the protein C amino acids affected by the mutations are very important for the in vivo expression of the antithrombotic properties of protein C.


Sign in / Sign up

Export Citation Format

Share Document